GSK to buy rare cancer drug developer IDRx for up to £1bn - MSN
GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts …
OFF
GSK To Buy Rare Cancer Drug Developer IDRx For Up To £1bn - MSN
2 weeks from now
GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts …
msn.com
OFF
GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion
2 weeks from now
2 days ago · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines.. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …
bloomberg.com
OFF
GSK To Buy U.S. Rare Tumor Specialist IDRx For Up To $1.15 Billion
2 weeks from now
2 days ago · GSK is buying privately-owned U.S. rare-tumor specialist IDRx for up to $1.15 billion, boosting its gastrointestinal cancer portfolio. The pharmaceutical giant said Monday that it will …
morningstar.com
OFF
GSK Nears $1bn Deal For Biotech Developing Drug For Rare Tumour
2 weeks from now
Jan 8, 2025 · GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours, as the UK drugmaker races to expand its oncology business. ...
ft.com
OFF
GSK To Buy U.S. Rare Tumor Specialist IDRx For Up To $1.15 Billion
2 weeks from now
2 days ago · GSK is buying privately-owned U.S. rare-tumor specialist IDRx for up to $1.15 billion, boosting its gastrointestinal cancer portfolio. The pharmaceutical giant said Monday that it will …
marketscreener.com
OFF
GSK Buys US-based Rare Cancer Treatment Developer For Up To £1bn
2 weeks from now
2 days ago · The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal cancers. Newsletters; Jobs; Cars; Homes; Book An Ad; Local …
thewestonmercury.co.uk
OFF
GSK’s Experimental Cancer Drug Wins Receives Support From US …
2 weeks from now
Jan 7, 2025 · Osteosarcoma is rare, with fewer than 1% of new US cancer cases annually, but it has a high recurrence rate, leaving patients with limited options after chemotherapy. GSK’227 …
proactiveinvestors.com
OFF
GSK To Buy Rare Cancer Drug Developer IDRx For Up To £1bn
2 weeks from now
2 days ago · GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the …
thisismoney.co.uk
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
